Literature DB >> 10829046

Declining cancer rates in the 1990s.

R McKean-Cowdin1, H S Feigelson, R K Ross, M C Pike, B E Henderson.   

Abstract

PURPOSE: To provide evidence of a substantial decline in cancer rates for the period 1991 through 1995 and characterize major risk factors that seem to be driving secular trends in cancer mortality and incidence.
DESIGN: Incidence and mortality rates were calculated using national surveillance data collected through the Surveillance, Epidemiology, and End Results (SEER) program and the National Center for Health Statistics.
RESULTS: All-sites cancer incidence and mortality fell in the period 1991 through 1995; this decline is largely attributable to decreases in the smoking-related cancers, especially lung cancer. Of the 20 leading incident cancers today, both incidence and mortality are decreasing among 11 sites for men and 12 for women. In men, the decline in mortality has been notable and is especially apparent for the smoking-related cancers, including those of the lung, oral cavity and pharynx, larynx, and, to a lesser extent, bladder. In women, all-sites mortality decreased only approximately 0.4% from 1991 through 1995. Three cancers continued to show substantial increases in mortality through 1995 for both men and women (liver, multiple myeloma, and non-Hodgkin's lymphoma), while incidence rates continued to climb for liver cancer, non-Hodgkin's lymphoma, and melanoma.
CONCLUSION: Data from the SEER program on recent trends in cancer incidence and mortality show that cancer rates are generally on the decline, largely because of reductions in smoking-related cancers. A consistent increase in mortality rates due to liver cancer poses a new health care challenge, one that will require the development of an effective treatment for individuals currently infected with hepatitis C or B to prevent mortality rates from continuing to increase.

Entities:  

Mesh:

Year:  2000        PMID: 10829046     DOI: 10.1200/JCO.2000.18.11.2258

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Impaired interferon-gamma production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma.

Authors:  Michael J Robertson; Hua-Chen Chang; David Pelloso; Mark H Kaplan
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  Preoperative predictors of survival after resection of small hepatocellular carcinomas.

Authors:  Jeffrey D Wayne; Gregory Y Lauwers; Iwao Ikai; Dorota A Doherty; Jacques Belghiti; Yoshio Yamaoka; Jean-Marc Regimbeau; David M Nagorney; Kim-Anh Do; Lee M Ellis; Steven A Curley; Raphael E Pollock; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2002-05       Impact factor: 12.969

3.  The role of DNA repair capacity in melanoma skin cancer risk in a population chronically exposed to high levels of sunlight.

Authors:  Jaime L Matta; Giovanna Rodriguez; Jaime Villa; Abigail Ruiz
Journal:  Ochsner J       Date:  2010

Review 4.  Efficacy and economics of hormonal therapies for advanced breast cancer.

Authors:  Michael S Simon; Dina Ibrahim; Lisa Newman; Miron Stano
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 5.  Workgroup report: base stations and wireless networks-radiofrequency (RF) exposures and health consequences.

Authors:  Peter A Valberg; T Emilie van Deventer; Michael H Repacholi
Journal:  Environ Health Perspect       Date:  2006-11-06       Impact factor: 9.031

6.  Trends and variations in breast and colorectal cancer incidence from 1995 to 2011: a comparative study between Texas Cancer Registry and National Cancer Institute's Surveillance, Epidemiology and End Results data.

Authors:  Zheyu Liu; Yefei Zhang; Luisa Franzin; Janice N Cormier; Wenyaw Chan; Hua Xu; Xianglin L Du
Journal:  Int J Oncol       Date:  2015-02-06       Impact factor: 5.650

Review 7.  HPV in oropharyngeal cancer: the basics to know in clinical practice.

Authors:  S Elrefaey; M A Massaro; S Chiocca; F Chiesa; M Ansarin
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-10       Impact factor: 2.124

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.